LIGAND PHARMACEUTICALS INCORPORATED Debt Securities, Available-for-sale, Unrealized Gain (Loss)
LIGAND PHARMACEUTICALS INCORPORATED (LGNDZ) reported Debt Securities, Available-for-sale, Unrealized Gain (Loss) of -$67.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-28.
Discontinued › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss · last filed 2023-02-28
- LIGAND PHARMACEUTICALS INCORPORATED debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2022-03-31 was -$114.00K.
- LIGAND PHARMACEUTICALS INCORPORATED debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2021-09-30 was -$14.00K.
- LIGAND PHARMACEUTICALS INCORPORATED debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2021-06-30 was -$5.00K, a 100.18% decline year-over-year.
- LIGAND PHARMACEUTICALS INCORPORATED debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2021-03-31 was -$55.00K.
- LIGAND PHARMACEUTICALS INCORPORATED debt securities, available-for-sale, unrealized gain (loss) for fiscal 2022 was -$67.00K.
- LIGAND PHARMACEUTICALS INCORPORATED debt securities, available-for-sale, unrealized gain (loss) for fiscal 2021 was -$116.00K.
- LIGAND PHARMACEUTICALS INCORPORATED debt securities, available-for-sale, unrealized gain (loss) for fiscal 2020 was -$162.00K, a 181.00% decline from fiscal 2019.
- LIGAND PHARMACEUTICALS INCORPORATED debt securities, available-for-sale, unrealized gain (loss) for fiscal 2019 was $200.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 3 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 6 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 9 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2022-12-31 | -$67.00K 10-K · filed 2023-02-28 | |||
| 2022-03-31 | -$114.00K 10-Q · filed 2022-05-09 | |||
| 2021-12-31 | -$116.00K 10-K · filed 2023-02-28 | |||
| 2021-09-30 | -$14.00K 10-Q · filed 2021-11-09 | -$19.00K derived: sum of 2 quarters · filed 2021-11-09 | -$74.00K derived: sum of 3 quarters · filed 2022-05-09 | |
| 2021-06-30 | -$5.00K 10-Q · filed 2021-11-09 | -$60.00K derived: sum of 2 quarters · filed 2022-05-09 | ||
| 2021-03-31 | -$55.00K 10-Q · filed 2022-05-09 | |||
| 2020-12-31 | -$162.00K 10-K · filed 2023-02-28 | |||
| 2020-09-30 | -$54.00K 10-Q · filed 2021-11-09 | $2.69M derived: sum of 2 quarters · filed 2021-11-09 | -$84.00K derived: sum of 3 quarters · filed 2021-11-09 | |
| 2020-06-30 | $2.74M 10-Q · filed 2021-11-09 | -$30.00K derived: sum of 2 quarters · filed 2021-11-09 | ||
| 2020-03-31 | -$2.77M 10-Q · filed 2021-11-09 | |||
| 2019-12-31 | $200.00K 10-K · filed 2022-02-28 | |||
| 2019-09-30 | -$187.00K 10-Q · filed 2020-11-06 | $316.00K derived: sum of 2 quarters · filed 2020-11-06 | $546.00K derived: sum of 3 quarters · filed 2020-11-06 | |
| 2019-06-30 | $503.00K 10-Q · filed 2020-11-06 | $733.00K derived: sum of 2 quarters · filed 2020-11-06 | ||
| 2019-03-31 | $230.00K 10-Q · filed 2020-11-06 | |||
| 2018-06-30 | -$495.00K 10-Q · filed 2019-11-08 | -$605.00K derived: sum of 2 quarters · filed 2019-11-08 | ||
| 2018-03-31 | -$110.00K 10-Q · filed 2019-11-08 |